NEW YORK (GenomeWeb) – Horizon Discovery has formed a strategic partnership with Axol Bioscience to develop and commercialize genomically modified and differentiated induced pluripotent stem cells (iPSCs) for neuronal and cardiovascular research, the companies announced today. 

"This partnership builds on Axol’s strong position in the use of stem cell technology, and the combination of Horizon's gene editing expertise with Axol's experience in working with iPSCs will offer valuable new tools for researchers," Axol Chief Business Officer Sanj Kumar said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.